"LCPN a novel oral testosterone undecanoate formulation has been shown to be safe and efficacious for the treatment of hypogonadal patients according to a study being presented during the th Annual Scientific Meeting of the American Urological Association AUA.  American Urological Association  The research will be highlighted by study authors during a special press conference to be moderated by Tobias S. Khler MD MPH FACS AUA spokesperson and associate professor of Surgery at Southern Illinois University on May   at  a.m. PT in the San Diego Convention Center.  Testosterone therapy is used to treat men with clinically diagnosed testosterone deficiency serum T levels  ngdL also known as hypogonadism. It is often administered as a gel patch injection or implant pellet. There is currently no oral form of testosterone therapy approved for use in the United States by the Federal Drug Agency however researchers from Houston TX and Torrance CA have been evaluating the longterm safety and tolerability of LPCN  a novel oral testosterone undecanoate formulation for the treatment of low testosterone. Throughout a week study period a total of  hypogonadal men were randomized either to LPCN  or T gel active control. Of the  men  were randomized to LPCN  and  were randomized to active control. Following a week efficacy phase men continued to receive their assigned treatment for up to  weeks. They returned at weeks   and  for safety assessments which included an evaluation of adverse events clinical laboratory tests and physical examinations.   Results showed  LPCN  was well tolerated and had a favorable safety profile in the longterm management of hypogonadal patients   No hepatic cardiac or drugrelated serious adverse events were reported   The most common drugrelated adverse events for LPCN  and T gel . percent were acne . percent vs. . percent respectively headache . percent vs. . percent respectively weight increase . percent vs.  percent respectively hematocrit increase . percent vs.  percent respectively liver enzyme level increase . percent vs.  percent respectively fatigue . percent vs. . percent respectively and hypertension . percent vs. . percent respectively   Lipid parameters i.e. cholesterol LDL HDL and TG were comparable between treatment groups at Week    Androgenic parameters including hematocrit hemoglobin platelet prothrombin and prostatespecific antigen PSA showed no significant differences in change from baseline to end of study between treatments  Based on the results of this study we might be closer than ever to having an oral form of therapy to treat the millions of men with hypogonadism said Dr. Khler.  Making sure an oral treatment is safe and effective for men and for the children and partners at risk for inadvertent testosterone transference is the top priority and what weve found so far has shown were on the right track.  About the American Urological Association The th Annual Meeting of the American Urological Association takes place May    at the San Diego Convention Center in San Diego CA.  Founded in  and headquartered near Baltimore Maryland the American Urological Association is a leading advocate for the specialty of urology and has more than  members throughout the world. The AUA is a premier urologic association providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education research and the formulation of health policy.  Related Links http"